You are here: Industry Insights > Ionis Pharmaceuticals

News List

Phase III trial to study familial chylomicronemia syndrome drug initiated europeanpharmaceuticalreview
December 03, 2020
Ionis Pharmaceuticals’ Phase III trial to evaluate AKCEA-APOCIII-LRx in patients with familial chylomicronemia syndrome has begun.
Pfizer Initiates Study of Vupanorsen americanpharmaceuticalreview
November 12, 2020
Ionis Pharmaceuticals and its wholly owned subsidiary Akcea Therapeutics announced Pfizer has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and ..
Ionis Pharmaceuticals licenses second antisense GI Drug to Janssen biospectrumasia
November 20, 2017
Under its global collaboration agreement with Janssen, Ionis is eligible to receive nearly $800 million in development, regulatory and sales milestone payments and license fees
Ionis urges investors to reject TRC Capital mini-tender fiercebiotech
August 25, 2017
Ionis says TRC's offer is below market price and lacks protections.
GSK walks away from Ionis antisense drugs pharmatimes
August 15, 2017
GlaxoSmithkline has turned down options to take on board Ionis Pharmaceuticals' experimental antisense therapies inotersen and IONIS-FB-LRx following a pipeline revamp.
GSK jilts Ionis rare disease drug as FDA filing nears fiercebiotech
August 14, 2017
GlaxoSmithKline has jilted Ionis Pharmaceuticals just before the pair was due to file for approval of inotersen. The action furthers recently installed GSK CEO Emma Walmsley’s plan to purge the Big Pharma of its rare disease programs.
Ionis and Ribo partner to commercialise RNA-targeted therapeutics in China pharmaceutical-technology
April 24, 2017
Ionis Pharmaceuticals has entered a collaboration and licence agreement with Suzhou Ribo Life Science (Ribo) to develop and commercialise ribonucleic acid (RNA)-targeted therapeutics in China.